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Observation of adverse drug reactions during drug development can cause closure 
of the whole programme.  However, if association between the genotype and the 
risk of an adverse event is discovered, then it might suffice to exclude patients of 
certain genotypes from future recruitment.  Various sequential and non-sequential 
procedures are available to identify an association between the whole genome, or at 
least a portion of it, and the incidence of adverse events.  In this paper we start with 
a suspected association between the genotype and the risk of an adverse event and 
suppose that the genetic subgroups with elevated risk can be identified.  Our focus 
is determination of whether the patients identified as being at risk should be 
excluded from further studies of the drug.  We propose using a utility function to 
determine the appropriate action, taking into account the relative costs of suffering 
an adverse reaction and of failing to alleviate the patient’s disease.  Two illustrative 
examples are presented, one comparing patients who suffer from an adverse event 
with contemporary patients who do not, and the other making use of a reference 
control group. We also illustrate two classification methods, LASSO and CART, for 
identifying patients are risk, but we stress that any appropriate classification 
method could be used in conjunction with the proposed utility function.  Our 
emphasis is on determining the action to take rather than on providing definitive 
evidence of an association.  
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1. INTRODUCTION 
The incidence of adverse events (AEs) is carefully monitored throughout the 
development of any new drug.  Occurrence of too many AEs of sufficient severity 
relative to the condition under treatment might lead to cessation of the whole 
programme of clinical evaluation.  However, now that routine genotyping has become 
available, it is possible to investigate whether emerging AEs are associated with a 
particular genetic subgroup of patients, opening up the possibility of continuing the 
programme once that subgroup has been excluded.   
In this paper we consider a drug development programme in which an 
association between the genotype and the risk of an AE is suspected.  Suspicion might 
have been aroused in a variety of ways.  An unexpectedly high rate of AEs might 
have led to a global comparison of the genomes of the patients who have had an 
adverse event with those of all or some of the patients who have not had an adverse 
event.  A number of genomewide association methods have been proposed [1-4] 
which could be used. Alternatively, sequential testing might have been conducted 
from the outset as new adverse events arose, perhaps using the approach of [5].  
Once an association between genotype and the risk of AEs is suspected within 
an ongoing drug development project, it is imperative that continuation of the 
programme of clinical research be reviewed.  It is not appropriate at this stage to 
demand rigorous and definitive statistical proof of the association, nor necessary to 
establish a detailed scientific understanding of its nature.  The pragmatic question is 
whether the research can continue to recruit from all, or from some, of the original 
patient population.  The answer will depend on the relative costs of experiencing the 
AEs and of withholding the treatment, and on estimates (albeit rough) of the risks of 
AEs within various genetic groups of patients. 
 2 
We shall refer to patients who suffer AEs in a drug development programme 
as “cases”, while patients who do not are “controls”.  When the latter come from the 
same clinical studies as the cases then they will be referred to as “concurrent 
controls”.  Sometimes it is more practical to compare cases with subjects from a 
reference population that has already been genotyped and whose data are readily 
available from an existing database: such patients will be referred to as “reference 
controls”.   
It could be that all patients in the drug development programme are routinely 
genotyped.  Then cases can be compared directly with concurrent controls and the 
probabilities of AEs within specific genetic groups can be estimated from the 
programme data alone.  Alternatively, genetic data might be available (or acquired) 
from all of the cases, but from only a subset of the concurrent controls, or patients 
with AEs might be compared with reference controls.  Subsequent analysis will then 
depend on the assumption that the controls used are otherwise comparable with the 
cases, and external information about the overall risk of an AE will be required.  
Given these two conditions, case-control techniques can be used to estimate the 
probabilities of AEs within genetic groups.   
Sometimes, suspicion of an association between the genotype and the risk of 
an AE will be based on a test which controls the type I error rate.  This is desirable, as 
the chances of unnecessarily excluding genetic groups from clinical research are then 
limited.  An example of a test that controls type I error through monitoring of this 
association throughout the development programme, is given by [5].  However, 
unplanned analyses with uncontrolled error rates might become ethically necessary, 
and they will lead to the same imperative for a review of study inclusion criteria. 
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In this paper we propose a method for deciding which genetic subgroups, if 
any, should be excluded from further clinical study, and whether their exclusion is 
sufficient to allow continuation of drug development. The proposed method is based 
on utility functions reflecting the cost-benefit balance associated with excluding 
specific genetic groups.  Once genetic subgroups that should be excluded have been 
identified, the new exclusion rule will apply to all new patients recruited to clinical 
studies, and their eligibility will have to be assessed prior to randomisation.  A policy 
will also be needed for patients who fall into the exclusion group who have already 
been randomised to treatment.  This will concern whether existing patients are to be 
retrospectively genotyped and whether any action is needed for patients who are now 
off treatment.  This issue is important, and could affect the final analysis of ongoing 
trials, but it lies outside the remit of this paper. 
In order to determine whether any genetic subgroup should be excluded, we 
must first identify the covariates that appear to be associated with higher risk. Any 
classification method could be used for this purpose.  If only a limited number of 
covariates are being considered, then standard logistic regression analysis could be 
applied.  However, if many potential covariates under consideration, such as hundreds 
of thousands of SNPs, then more sophisticated classification methods will be needed.  
The methods described in this paper have been motivated by the availability of 
whole genome data, but they are applicable to a wide range of factors with potential 
for association with the risk of AEs.  For other high dimensional assessments 
(genomics, transcriptomics, proteomics and so on) the situation would be similar to 
that described here.  More conventional risk factors, such as age and gender, could be 
added to the list of covariates.   
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Section 2 is devoted to the development of the utility function for deciding 
whether to exclude patients, and this forms the core of the paper.   Section 3 describes 
possible approaches for identifying genetic subgroups with differing AE risks which 
can be used in the application of the proposed utility function approach. Two options 
are considered, the LASSO method and CART, but these are by no means the only 
possibilities. These classification methods are used in the illustrations presented in 
Section 4, while Section 5 is a discussion of the methodology and its implications. 
As mentioned above, we are not concerned with making scientifically rigorous 
and definitive claims about associations between the genome and AEs.  That is an 
important but different problem, [6-7].   In the context of ongoing clinical research, if 
it appears that some genetic subgroups are at high risk of AEs, then it is essential that 
the options of excluding those patients are urgently explored.  Possible conclusions 
will be to exclude no-one, to exclude everyone and thus terminate the drug 
development programme, or to exclude a specific subset.   
 
2. EXCLUSION OF PATIENTS BASED ON A UTILITY FUNCTION 
Suppose that an association between the genome and the risk of an AE is suspected, 
and that it is necessary to identify which patients should be excluded from further 
clinical studies.  It may be that no patients are excluded or that all of them are.  The 
exclusion criterion will be defined in terms of genotype, and S will denote the set of 
genotypes associated with those patients to be excluded.  The
 
form of S is determined 
to maximise a utility function, which will now be defined.  Consequently, all 
subsequent patients in the programme will have to be genotyped prior to entry. 
Let D be the event of “having the disease”.  More precisely, D denotes the 
event that a patient’s condition is not alleviated in the way that would be expected if 
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the novel drug were administered and was efficacious.  Reality is simplified by 
supposing that all patients can be classified as either experiencing event D or event 
D (not D).  On the other hand, it will be allowed that both patients receiving the drug 
and those not receiving it may have event D.  The event of having an AE (of a 
specific, pre-defined type) is denoted by A.  In this section it will be supposed that the 
event A can occur for patients receiving the drug and for those not receiving it, with 
the probability of A depending both on whether or not patients receive the drug and 
on their genotype.   
The cost of event D will be denoted by d and that of event A by a.  These 
notional costs can be fixed subjectively, and what will turn out to be important is their 
ratio a/d: how serious the adverse event is relative to failure to control the disease.  
The value of this ratio should be determined from discussion with experts in the 
clinical area.  It will be supposed that the cost of experiencing both D and A is d + a, 
although a more general, non-additive approach could easily be developed.  We also 
assume that the events D and A occur independently, conditional on treatment. 
Suppose that patients can be classified into k genetic groups with distinct risks 
of event A.  Some methods for doing this will be described in Section 3.  Consider a 
patient who lies in the genetic group g.  In terms of the events D and A, the expected 
cost of administering the drug is d P(D| g, E) + a P(A| g, E), where E is event of 
administering the drug (E).  The expected cost of withholding the drug is d P(D| g, E ) 
+ a P(A| g, E ).  The patient should be excluded if the former exceeds the latter.  Let 
h(g) denote the probability that a patient in the drug development programme has 
genotype g.  Then the utility, per patient, of excluding all patients in genetic group g 
for all g in the set S is 
 
g s
U h(g) d P(D | g,E) a P(A | g,E) d P(D | g,E) a P(A | g,E) . 
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Thus U is the difference, per patient, between the expected cost of administering the 
drug and the expected cost of withholding the drug for patients with genotypes in the 
set S.   The set S should be chosen to maximise U, which can be achieved by 
excluding patients in genetic group g if P(A | g,E) P(A | g,E)  
d / a P(D | g,E) P(D | g,E) .   If D depends on treatment, but not on genotype, then 
dependence on g can be removed from the right-hand side of this expression, and a 
patient in genetic group g will be excluded if 
 
d
P(A | g,E) P(A | g,E) P(D | E) P(D | E) .
a
                                           (1) 
The difference P(D | E) P(D | E)  represents the treatment effect.  This might be 
estimated from existing data.  Alternatively, if only limited data are available when 
the association between genotype and AE risk is first suspected, an anticipated 
treatment effect based on expert opinion or previous relevant data might have to be 
used instead. 
The probabilities h(g) associated with each genetic group are estimated by the 
proportions of each genetic group within the combined population of cases and 
controls.  When reference controls or just a sample of concurrent controls are used, 
then the validity of these estimates depends on the assumption of comparability 
between the controls and patients in the drug development programme.  If genetic 
data are available from all cases and concurrent controls, then estimates of 
P(A | g,E) and P(A | g,E)  can be obtained directly.  If the genetic data are available 
from cases and a sample of concurrent controls or of reference controls, giving a 
population , then direct estimates can be obtained for P(A g, ).  The following 
approach, familiar from drawing inferences from matched case-control studies [8] can 
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then be used to estimate the P(A g, E).  Suppose that the genetic groups identified 
form the set {g1,…, gk}.  It is shown in Appendix 1 that  
 
i j i j
j i j i
P A g ,E P A g ,E P A g , P A g ,
P A g ,E P A g ,E P A g , P A g ,
.                                      (2) 
Now denote P(A gj, E) by pj, j = 1, ..., k, and denote the right-hand side of (2) by 
ORij.  It follows that 
1 2 12 2 1
1 k 1k k 1
p 1 p OR p 1 p
                   
p 1 p OR p 1 p
                                                                             (3) 
and it is also true that 
1 1 k kh g p ... h g p P A E .                                                                  (4) 
Now OR12, ..., OR1k will be known from the classification method, P(A E) is known 
from external sources and h(g1), ..., h(gk) are estimated from the genome data.  Thus, 
solving for p2, …, pk from (3) and substituting into (4), we obtain an equation in p1 
alone, that can be solved using a simple numerical search.   The same method can be 
used with E replaced by E  to estimate the P(A | g,E) . Note that if P(A|gj, ) = 0 or 1 
then pj = 0 or 1 respectively, and (3) has then to be solved for the remaining unknown 
probabilities.  Of course, when reference controls are used, the unrepresentative mix 
of cases and controls will also have an effect on the estimation of the h(gi): it might be 
desirable to used a weighted average of separate estimates from cases and controls, 
weighted according to the external value of P(A E). 
 A very simple case of this approach occurs when a single SNP is used to 
identify three genetic groups based on whether the genotype at that SNP is aa, Aa or 
AA.  Expression (1) can then be used to identify whether patients from any of these 
three groups should be excluded. There may be a well known candidate SNP which 
 8 
can be investigated in this way.  A naive extension of this idea is to explore which 
groups of patients should be excluded on the basis of each of a number of SNPs, 
considered separately, one at a time, in this way.  This will give one exclusion set for 
each SNP.  Then any patient falling in any of these exclusion sets would be excluded.  
Although this might appear to be a sensible strategy, it is based on separate marginal 
analyses and is thus oblivious to the joint influences of the SNPs.  The identification 
methods described in Section 3 overcome this limitation by taking into account the 
whole cross-classification of genetic groups, rather than just the marginal 
classifications.   
 
3. METHODS FOR IDENTIFYING GENETIC GROUPS AND 
ESTIMATING THEIR ADVERSE EVENT RISKS  
Computation of the utility defined above requires division of the population into a 
number of genetic subgroups that are homogeneous with regard to AE risk, while 
differing between one another in this respect.  Also needed are the estimates of the AE 
risks for each genetic group.  The problem to be overcome is the sheer number of 
potential prognostic factors arising from the genome scan, usually far more than there 
are patients.  Many methods have been suggested for overcoming this difficulty [9], 
and our concern here does not lie with creating new methods nor reviewing those that 
already exist. Readers may choose their own favourite approach for this step.  In this 
section we describe two methods that could be used, in preparation for the 
illustrations of Section 4.  In common with most such procedures, neither make 
explicit use of potential dependence (linkage disequilibrium) between the covariates 
arising from different SNPs, but they do lead to models which are valid in the 
presence of such dependence.  Throughout this section the term yi takes the value 1 if 
 9 
the i
th
 patient has suffered an AE and 0 otherwise, i = 1, 2, …, n and  zi = (zi1, …, zip)  
denotes the corresponding genotype data, where  zij denotes the genotype for the i
th
 
patient at locus j, taking a value of  0, 1, or 2 depending on whether the patient’s 
genotype at that locus is aa, Aa or AA respectively.   In a regression model to fit a 
dominant or recessive genetic model, zij will be replaced by xij taking just one of the 
values 0 or 1.  In a general genetic model that has no restrictions, zij can be replaced 
by two independent variables xi,j(a) and xi,j(b) to define the genetic structure.  In the 
examples of Section 4 xi,j(a) takes the value 0 for aa and 1 otherwise, while xi,j(b) takes 
the value 0 for aa or Aa and 1 otherwise.  
 
3.1   The least absolute shrinkage and selection operator (LASSO)  
The LASSO method was proposed for normally distributed data by Tibshirani [10] for 
estimation in linear models when the number of independent variables is large.  The 
approach has been extended to the case in which the number of independent variables 
exceeds the number of observations [11, 12].  The method consists of maximising the 
likelihood, subject to a penalty term concerning the size of the fitted coefficients.  The 
LASSO achieves accurate prediction by shrinking some coefficients and setting others 
to zero.  A logistic regression version of the LASSO method was described by Genkin 
et al. [13] in which the linear model i ilogit p( ) ( )x x =  + xi is fitted, where 
p(xi) = P(Yi = 1 xi) and  = ( 1, ..., p)  is a vector of unknown coefficients.  The 
logistic LASSO estimate of the coefficients ˆˆ( , )  is the value of ( , )  maximising 
the penalized log-likelihood 
p
j
j 1
S ( , ) ,   
where  ≥ 0 is called the tuning parameter and  is the log-likelihood function:  
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n
i i i
i 1
( , ) y ( ) log 1 exp ( )x x . 
The higher the value of , the fewer the number of terms appearing in the model.  For 
the general genetic model, it may be felt desirable to ensure that either both 
independent variables relating to a single locus, xi,j(a) and xi,j(b), are in the model or 
that neither is.  Yuan and Lin [14] extended the LASSO method to incorporate this 
restriction, so that ˆˆ( , )  is chosen to maximise  
q
1/ 2
2 2
j,a j,b
j 1
S ( , ) ,   
where q = p/2 (that is, there are q SNPs and p = 2q coefficients).  It is debatable 
whether such pairs of independent variables need to be kept together and either option 
could be taken: in the example of Section 4.1 below, we have not made this 
restriction.  The routine penalized [15] in the software R [16] has been used in this 
paper to implement the LASSO method.   
 
3.2   Classification and Regression Trees  
A Classification And Regression Tree (CART) is an alternative tool for uncovering 
structure in data whenever a single response is to be related to many explanatory 
variables [17-18].  In R, CART may be implemented using the tree routine [19].   In 
the setting of this paper, the i
th
 patient provides the binary response yi and the vector 
of genetic variables zi = (zi1, …, zip) , which can either be assumed to be continuous or 
factor explanatory variables. Each patient is classified into one of k disjoint genetic 
groups, {g1, ..., gk} on the basis of the values of some chosen subset of the genetic 
variables.   The model is fitted using binary recursive partitioning, whereby the data 
are successively split along coordinate axes of the predictor variables.  Each split is 
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referred to as a “node” of the tree, and the final groups are referred to as “terminal 
nodes”.  At each node, the split which maximises some measure of the difference 
between the response variables in the left and the right branches, is selected.  Splitting 
continues until the terminal nodes either become homogeneous, that is to say the 
within-node deviance becomes too small to be worthwhile splitting further, or they 
contain too few observations (that is fewer than some pre-specified limit).  Both of 
these criteria are set manually, and for the R tree routine, the default values are 0.01 
and 10, respectively. The terminal nodes are called “leaves”, while the initial node is 
called the “root”. The resulting classification can be displayed in the form of a binary 
tree. 
   
3.3   Missing Values 
Missing values in the data might occur in the genotype data due to, for example, poor 
DNA quality, differential PCR amplification or uncertain genotype calling.  The R 
routine penalized cannot be used when the explanatory variables have missing 
values.  In order to prepare the dataset for use of the LASSO on the examples in 
Section 4, the K nearest neighbours (KNN) method of Troyanskaya et al. [20] was 
used for imputation.  If the value of the xiv, the v
th
 explanatory variable for the i
th
 
patient is missing, then this method finds the K other patients, who do have values for 
this explanatory variable, who are most similar to the i
th
 patient with respect to the 
other explanatory variables.  Similarity is assessed in terms of a distance measure: 
here the Euclidean distance, dim = 
2
ij mj
j
x x was adopted.  An average of values 
of the xjv for values of j corresponding to the K most similar patients is then used as 
an estimate for the missing value of xiv.  Note that imputed values may be non-integer 
and will then have no literal genetic interpretation.   
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For the CART approach, the handling of missing values is straightforward. 
Missing values can be classified as another level in the factor, or they can be ignored 
when splitting [19].  The latter approach is used for the example in Section 4.   
 
4.    EXAMPLES 
The examples in this section are based on data extracted from two GlaxoSmithKline 
(GSK) trials of abacavir in the treatment of HIV infection (CNA30027 and 
CNA30033).  They concern a subset of the patients who received the active drug and 
were genotyped and they have already been used in the illustration of reference [5].  
The adverse event of interest is taken to be incidence of hypersensitivity.  The data 
comprise genotype information from 856 loci for 593 controls and 530 cases.  The 
trial scenario has been modified and simplified for illustrative purposes, and in the 
following subsections two extreme sampling situations are described in order to bring 
out the essential features of the approach.  Because of these manoeuvres, conclusions 
drawn from the examples may not be relevant to the use of abacavir, and so we refer 
only to “active drug” in most of what follows.  
 According to expression (1), future patients should be excluded from clinical 
studies if P(A | g,E) P(A | g,E) d / a P(D | E) P(D | E) .  Hypersensitivity 
cannot occur amongst untreated patients, although it may be falsely diagnosed.  For 
the purpose of the illustration in this section we suppose that no such diagnoses were 
found in the placebo group, or that such patients have been discounted in the analysis, 
so that P(A | g,E)  = 0.  The methodology of Section 2 allows a more delicate analysis 
to be undertaken, in which P(A | g,E)  is also estimated.  Apart from P(A | g,E) , the 
remaining terms in this expression will be determined from external sources.  The 
values of P(D | E) and P(D | E)  cannot usually be found from the clinical trial data, as 
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these are likely to be too limited and too short-term to support reliable estimates.  
Data from other studies might be used, or hypothesised values used in the trial design.  
Here we will rely on therapeutic response rates to abacavir in three trials (CNA30021, 
30024 and CNA3005) specified on the US package inserts as of June 2007.  These 
range from 49% to 69%.  We shall take P(D | E) P(D | E)  = 0.5, assuming 
therapeutic response is rare in the placebo group.  It will be assumed that a = 5d, 
indicating that incidence of hypersensitivity is five times as bad as failing to 
experience a therapeutic response. Thus patients should be excluded if P(A g, E) > 
0.1. In the example below, the classification methods have been implemented in R, 
using the default options for LASSO and CART, unless otherwise stated. In the first 
example below LASSO is used for the classifying of patients into genetic groups, 
while CART is used for the second example. This is done for illustrative purposes 
only, showing that any type of classification method can be used in conjunction with 
the utility approach; either classification method could have been used for both 
examples below.  
 
4.1  Applying the LASSO in an illustration based on using all concurrent controls 
For the first example, consider a prospective drug development program in which 
patients are randomised between active drug and placebo.  All patients in the 
programme are routinely genotyped.  At some stage, concern is raised about the rate 
of hypersensitivity occurring amongst patients receiving active treatment.  The 
concern might have come from a formal monitoring procedure, from a Data and 
Safety Monitoring Board or from less formal considerations.  However it arose, it has 
become necessary to consider exclusion of patients on a genetic basis.  Suppose that 
concern is reached when 52 patients on active drug have suffered hypersensitivity and 
 14 
593 have not.  The overall probability of an adverse event is therefore 52/(52 + 593) = 
0.081. To illustrate this scenario, all of the patients who did not suffer AEs in the 
available dataset are used to represent 593 concurrent controls and 52 cases are 
selected from the 530 patients who did suffer an AE.  
The genetic groups and their associated AE risks will be found using the 
LASSO method in this illustration.  The KNN imputation method was applied to the 
data before model fitting began.  Then a general genetic model was fitted, with two 
dummy indicator variables being associated with each SNP.  For this illustration, the 
tuning parameter was fixed to be 9 in this illustration, which identified four SNPs 336, 
410, 825 and 847 to be influential.  In each case only one of the associated dummy 
variables was selected (as explained in Section 3, we chose not to require the pair of 
variables at each locus to be included or excluded together).  The following model 
was fitted: 
336a 410a 825b 847alog it{P(A | g,E)} 2.691 2.166x 0.018x 0.014x 0.079x , 
splitting patients into 16 genetic groups. As the 52 cases are being compared with 593 
concurrent controls on the active drug, and all patients in the trial are being 
genotyped, the fitted model concerns the population E.  Hence, fitted probabilities can 
be used directly in the computation of the utility of exclusion without recourse to 
equations (2) and (3).  The fitted values of P(A gi, E) and corresponding estimates of 
the h(gi) are listed in Table 1.   
As explained at the beginning of this section, patients should be excluded if 
P(A gi, E) > 0.1, which means only patients with x336a = 0, that is patients with allele 
of aa at locus 336, will be included.  Applying the exclusion rule to the dataset used to 
create it, we find that there are 23 patients amongst the 52 cases and 14 patients 
amongst the 593 controls who would be excluded according to this strategy, and the 
 15 
utility of the policy would be U = 0.0164a.  This is the utility per patient, so that the 
total utility if (say) 1000 more patients were now treated in the clinical research 
programme would be 16.4a: this strategy would be equivalent to saving more than 16 
per 1000 patients from suffering the AE.  Evaluation of the exclusion rule can be 
more accurately assessed using cross-validation: we used leave-one-out cross-
validation, leaving each of the 645 subjects out in turn, creating an exclusion rule as 
described above, and then classifing the remaining subject (the cvl function from the 
penalised package was used).   The cross-validation estimated that 24 patients 
amongst the 52 cases (46% sensitivity) and 19 patients amongst the 593 controls 
(97% specificity) would have been excluded.    Additionally, there were in fact 530 
cases (patients with AEs) in the dataset, of whom we have used 52.  Amongst the 478 
cases who were not used to build the model, a further 174 would be excluded by the 
rule that has been developed. 
Applying the exclusion policy will result in the inclusion of an estimated 
93.9% of future patients (found by summing the h(g) over g  S), who would face an 
estimated risk of 0.062 of an AE (found by summing h(g)  P(A g, E) over g  S and 
dividing by the sum of h(g) over g  S), compared with an estimated risk of 0.081 
without the exclusion policy.  Thus by excluding 6.1% of patients, the risk of AE is 
predicted to fall by 23%. 
  
4.2   Applying CART in an illustration based on reference  controls 
The second example concerns the situation described in [5] where, as each new case 
occurs, they are compared to a fixed group of reference controls according to a 
sequential procedure in which the overall type I error rate is controlled. Applying this 
method to the GSK data, the procedure is found to stop after observation of the 18
th
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case. Here, the 593 non-AE patients were used assuming these were reference 
controls and cases were taken randomly one at a time from the 530 AE patients. The 
remaining 512 AE-patients are used to see how effective the methods are at 
preventing would be “new” cases from receiving the drug.  
Since we are assuming that the controls are fixed, the population  (the 18 
cases and 593 controls) is not representative of E in terms of AE risk. Consequently, 
the probability of an adverse event for a given genotype group, gi, calculated from the 
18 cases and 593 controls represents P(A gi, ), rather than P(A | gi, E), and so we 
need to use Equations (3) and (4) to calculate the P(A | gi, E) before applying the 
exclusion criteria. To do this we require estimates of genotype frequencies, h(gi),  and  
an estimate of the overall adverse event rate, P(A | E). The values of h(gi) can be 
calculated from any relevant source of information, for the purpose of this illustration 
we calculate it using a weighted estimate, adding 0.08  the proportion cases in group 
gi to 0.92  the proportion of controls in group gi.  Such an average reflects the case-
control mix likely to be found in the general patient population, rather than the mix 
within the genotyped subjects available for the analysis.  The value for P(A | E) would 
in practice be found from external information, or from the clinical patient data 
observed so far, using AE information on all patients regardless of whether they have 
been genotyped or not.  Here, the value 0.08 is used for illustration as the overall 
probability of an adverse event.  (US prescribing information for abacavir describes a 
hypersensitivity rate of 8% in nine clinical studies between November 1999 and 
February 2002.)  A short-cut to the calculation that is available in this specific 
situation was used, and this is described in Appendix 2. 
Table 2 shows the classification into genotype groups produced using CART.   
The P(A gi, ) are the estimated probabilities produced by CART, and the P(A gi, E) 
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are derived from them using equations (3) and (4).  CART classifies patients into 11 
groups. The P(A gi, ) values for groups g1, g2,  g3, g5,  g6 and g9 are equal to zero, 
consequently the corresponding P(A|gi, E) values are also equal to zero.  All other 
P(A gi, ) values exceed 0.1.  Thus future patients in groups g4, g7, g8, g10 and g11 
should be excluded.  The corresponding regression tree is shown in Figure 1.  There 
are 17 patients amongst the 18 cases and 12 patients amongst the 593 fixed controls 
who would have been excluded according to this strategy.  Applying leave-one-out 
cross-validation results in the exclusion of 4 patients amongst the 18 cases (22% 
sensitivity) and 44 patients amongst the 593 fixed controls (93% specificity) who 
would have been excluded.     
Again we may use the remaining cases to indicate how the proposed method 
would perform amongst future patients who would suffer AEs if treated with the drug.  
Amongst the remaining 512 cases, 95 would be excluded.  Summing the h(gi) values 
in Table 2 over the genetic groups that would be excluded shows that application of 
an estimated 9.9% of all future patients would be excluded. 
 
5.   DISCUSSION 
This paper describes a pragmatic approach to the situation in which a suspicion of an 
association between the genome and the risk of an AE has arisen.  The future 
development of the drug will depend, not only on the existence of such an association, 
but also on its magnitude and on the relative costs of suffering the AE and of being 
denied the real or potential benefit of the drug.  Throughout this paper, the context has 
been a clinical drug development programme, and the objective one of modifying the 
exclusion criteria for patients yet to be randomised in order to reduce the incidence of 
AEs and allow continuation of the programme.  The possibility that such a 
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modification might lead to bias in the evaluation of the experimental drug has to be 
considered carefully.  Problems might arise in meta-analyses of trials before and after 
the change, but as investigators should always learn from past trials in designing new 
ones such difficulties may be inherent in any meta-analysis.  When the changes are 
instituted during the course of a trial, possibilities of bias must be addressed.  It might 
be that the principal endpoint used to assess efficacy is independent of the incidence 
of the AEs being considered, or at least any association might be regarded as so 
tenuous that independence can safely be assumed.  Otherwise, the possibility of bias 
has to be recognised.  It might be possible to overcome the problem using the methods 
of adaptive design, but this issue lies outside the scope of this paper.   
The emphasis of this paper is on the use of a utility function to determine the 
set of patients who should be excluded from further clinical studies, and probably 
from any future administration of the drug. In order to compute the utility it is 
necessary to identify genetic groups and to estimate the AE risks associated with 
them.  For this step, a variety of methods are available: the LASSO and CART 
methods considered above being just two candidates.   
The classification into genetic groups is taken as a pragmatic tool, and the 
estimation of the associated AE risks is clearly approximate.  The approach here will 
not stand up in terms of accuracy and reliability to comparison with approaches that 
can be applied retrospectively to completed studies in which there is no acute ethical 
need to decide who should and should not be included.  The risk estimates suffer from 
the problem that they are estimated from the same data that have been used to identify 
the genetic groups, leading to underestimation of risk following implementation of the 
exclusion policy.  The shrinkage element of the LASSO approach goes some way to 
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allowing for this, and cross-validation can been used to estimate exclusion rates more 
accurately.  
Both the LASSO and the CART approaches suffer from the problem of how to 
choose their respective settings.  The tuning parameter for the LASSO method has to 
be fixed, and in the example this was done in an arbitrary way.  One automatic 
criterion of choice is the K-fold cross-validation method described by [21, 22].  When 
applied to the example of Section 4.1, it results in the choice  = 7.74 and the 
identification of 2
8
 genetic groups!  Estimation of h(g) and P(A g, ) for so many 
groups is impractical given the limited data available.  In CART, the arbitrary settings 
concern when to stop splitting the nodes of the tree [17].  For either approach, it might 
be worth exploring the combination of the cross-validation criterion with a penalty 
based on the number of genetic groups identified, but this lies outside the scope of the 
present paper.  In this paper, settings have been chosen to yield a small and thus 
manageable set of genetic groups, and in practice this would appear to be a feasible 
approach.  An alternative approach to classification would be to use random forests: a 
method which automatically incorporates internal validation [23, 24]. 
Detection of a genetic association with AEs will not necessarily lead to action.  
It may be that there is no genetic group for which the utility of exclusion is positive.  
This could be the case if the cost of not controlling the disease is judged to be greater 
than the cost of the AE, for example when the disease is late stage cancer and the AE 
is simply a mild headache.  On the other hand, it may be that all genetic groups should 
be excluded: that is, the clinical development programme should be terminated.  The 
advantage of the method presented here is that it provides rationally based 
quantitative input into discussions which might otherwise be based only on informal 
clinical judgement.  
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A naive method based on considering each SNP separately was described in 
Section  2.  This was applied to the examples of Sections 4.1 and 4.2, and in each case 
it led to the exclusion of all future patients and thus closure of the drug development 
programme.  Rather than basing decisions on expected utility, as has been done here, 
other criteria such as minimax [25] could be considered.  The minimax criterion seeks 
a decision to minimise the maximum loss, or in the terminology used here, to 
maximise the minimum utility.  For every policy, the minimum utility is 
g S
d a h g , as the worst thing that might happen if denied treatment is that a 
patient might suffer both D and A, while the best thing that might happen if given 
treatment is to suffer neither D nor A.  The minimax criterion would then lead to the 
exclusion of no-one. 
The illustrations used in this paper are of necessity artificial.  The method has 
yet to be implemented in practice.  When it is, then the nature and completeness of 
data collection will be affected by the knowledge of their importance for safety 
monitoring and hopefully improved.  There are countless methodological 
improvements that could be made to the theory underlying the approach, but more 
valuable in its development would be experience from its use in real studies. 
Once a genetic association with AEs is suspected, and action to exclude 
certain genetic groups has been taken, the question arises of how further monitoring 
should proceed.  Could the approach be used again later in the drug development 
programme to identify further genetic groups for exclusion?  As each round of 
exclusions is of necessity based on limited data, should ways be found for readmitting 
excluded groups later in the process? 
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APPENDIX 1:  Indirect estimation of adverse event probabilities  
 
Suppose that the cases and controls cannot be used to provide estimates of the risk of 
AEs.  This might be because differential proportions of cases and controls are 
genotyped, or because the controls form a fixed group with genotype data available 
before the drug-development programme begins.  In the latter case, the fixed controls 
will be assumed to be of the same genetic mix as the patients to be entered into 
clinical trials, but they will not have been exposed to the drug and so will not have 
had AEs.   
Estimation of the P A g,E  for the various genetic groups can then be 
achieved following an approach used in epidemiology for matched case-control 
studies.  Consider two genotypes, g1 and g2.  Suppose that the data from the cases and 
from the available controls are pooled.  From this pool , we can estimate 
iP A g , , i = 1, 2, using LASSO, CART or some other approach.  Now 
 
i
i
i
P g A, P A
P A g ,
P g
, 
so that 
 
1 2 1
2 1 2
P A g , P g P g A,
P A g , P g P g A,
. 
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A similar equation holds for the event A , and so 
 
1 21 2
2 1 2 1
P g A, P g A,P A g , P A g ,
P A g , P A g , P g A, P g A,
. 
The same arguments apply to the population E of patients exposed to the active drug, 
so that 
 
1 21 2
2 1 2 1
P g A,E P g A,EP A g ,E P A g ,E
P A g ,E P A g ,E P g A,E P g A,E
. 
As we are assuming that the genetic make up of patients in  is the same as that of 
those in E, it follows that 
 
1 2 1 2
2 1 2 1
P A g ,E P A g ,E P A g , P A g ,
P A g ,E P A g ,E P A g , P A g ,
. 
This means that odds ratios estimated for the pooled population , will be valid for 
the population E.  Probabilities will not, because the proportion of patients with A in 
the population  is determined by the experimental design (in particular by the size of 
the chosen fixed group of controls, and does not reflect the risk of A).   
 
APPENDIX 2:  Indirect estimation of adverse event probabilities in the context of 
CART  
Let the external estimate of the risk of an AE be  = P(A E).  Suppose that, in the 
data available, there are nca,j cases and nco.j controls within genetic group gj, and that 
Nca = nca,1 + … + nca,k and Nco = nco,1 + … + nco,k.  A direct estimate of the probability 
of an AE in group gj would be p j = nca,j/(nca,j + nco.j), and a weighted estimate of the 
probability that a patient lies in group gj would be h(gj) = nca,j/Nca + (1  )nco.j/Nco.  
Put  
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pj = qnca,j/(qnca,j + nco,j), j = 1, …, k,                                                              (A1) 
where q = Nco /{Nca(1  )}.  As the direct odds ratios from CART are given by ORij 
= p i (1  p j)/{p j (1  p j)}, it is clear that the pj satisfy equation (3).  Furthermore 
 
ca, j co, j ca, j
j j
ca co ca, j co, j
co ca, j ca co, j co ca, j
ca co co ca, j ca co, j
ca, j
ca
n 1 n qn
h g p
N N qn n
N n 1 N n N n
             
N N N n 1 N n
n
             ,
N
 
so that the sum of these terms over j is equal to , as required by equation (4).  Thus, 
the required estimates pj can be found by direct evaluation from (A1), rather than 
from simultaneous indirect solution of equations (3) and (4). 
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Table 1: Results from the application of LASSO to the data of Section 5.1 
genetic 
group, gi 
specification of gi h(gi) P(A|gi,E) Controls 
excluded 
(from 593) 
Cases 
excluded 
(from 52) 
Cases 
excluded 
(from 478) 
x336a x410a x825b x847a 
g1 0 0 0 0 0.118 0.064    
g2 0 0 0 1 0.113 0.059    
g3 0 0 1 0 0.138 0.064    
g4 0 0 1 1 0.088 0.060    
g5 0 1 0 0 0.113 0.065    
g6 0 1 0 1 0.068 0.060    
g7 0 1 1 0 0.195 0.065    
g8 0 1 1 1 0.106 0.061    
g9 1 0 0 0 0.012 0.372 3 4  28 
g10 1 0 0 1 0.010 0.353 5 2  19 
g11 1 0 1 0 0.008 0.375 2 3  32 
g12 1 0 1 1 0.002 0.357 1 0  27 
g13 1 1 0 0 0.007 0.376 0 4  14 
g14 1 1 0 1 0.003 0.358 2 0  19 
g15 1 1 1 0 0.012 0.379 0 7  20 
g16 1 1 1 1 0.007 0.361 1 3  15 
 
U = a{  (0.012 + 0.010 + 0.008 + 0.002 + 0.007 + 0.003 + 0.012 + 0.007)  
0.1 + (0.012  0.372 + 0.010  0.353 + 0.008  0.375 + 0.002  0.357 
+ 0.007  0.376 + 0.003  0.358 + 0.012  0.379 + 0.007  0.361 )}  
    = 0.0164 a. 
 
In addition, imputation assigns the values x336a  = 1, x410a  = 0.25, x825b  = 1 and x847a  = 
0 to one case, and this patient would therefore also be excluded.
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 Table 2: Results from the application of CART to the data of Section 5.2 
 
 
Genetic 
group, gi 
specification of gi h(gi) P(A gi, ) P(A gi, E) Controls 
excluded 
(from 593) 
Cases 
excluded 
(from 18) 
Cases 
excluded 
(from 512) 
g1 x336=0;   x821=2; 
x751=0,2  
0.681 0.00 0.000 -  - 
g2 x336=0;   x821=2;     
x751=1;   x556=0,1  
0.116 0.00 0.000 -  - 
g3 x336=0;   x821=2; 
x751=1;   x556=2; 
x61=0,2     
0.023 0.00 0.000 -  - 
g4 x336=0;   x821=2; 
x751=1;   x556=2; 
x61=1      
0.017 0.60 0.811 2 3  5 
g5 x336=0;   x821=0,1; 
x437=0,2  
0.049 0.00 0.000 -  - 
g6 x336=0;   x821=0,1; 
x437=1;   x568=0,1; 
x809=0     
0.016 0.00 0.000 -  - 
g7 x336=0;   x821=0,1; 
x437=1;   x568=0,1; 
x809=1;     
0.011 0.20 0.417 4 1   2 
g8 x336=0;   x821=0,1; 
x437=1;   x568=2     
0.020 0.80 0.920 1 4   3 
g9 x336=1,2; x64=1      0.016 0.00 0.000 -  - 
g10 x336=1,2; x64=0,2;   
x169=1,2  
0.018 0.29 0.534 5 2 40 
g11 x336=1,2; x64=0,2;   
x169=0     
0.033 1.00 1.000 0 7 45 
 
U = a{  (0.017 + 0.011 + 0.020 + 0.018 + 0.033)  0.1 + (0.017  0.811 + 
0.011  0.417 + 0.020  0.920 + 0.018  0.534 + 0.033  1.00)}  
    = 0.0893a. 
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Figure 1:   The tree diagram arising from the application of CART to the data of Section 5.2.  The probability of being a case or control for the 
terminal nodes, gi are given in Table 2. 
